An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam
试验速览
- 阶段
- 3 期
- 状态
- 撤回
- 主要终点
- Percentage of Participants Achieving Sustained Virologic Response (SVR)
研究概览
简要总结
This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1.5 mcg/kg once a week (QW) administered subcutaneously (SC) plus ribavirin (RBV) (800 to 1400 mg/day) PO in Response Guided Therapy (RGT) in adult Vietnamese subjects with Chronic Hepatitis C, Genotype 1 (CHC GT1) who failed prior treatment with any interferon and ribavirin in Vietnam.
详细描述
Each participant will participate in the trial for a maximum of 80 weeks from the time the participant signs the Informed Consent Form (ICF) through the final contact. After a Screening phase of approximately 4 to 8 weeks, each participant will receive treatment for approximately 36-48 weeks depending on response at Treatment Week 8.
A 4-week lead-in period with PEG2b plus RBV will be followed by 32 weeks boceprevir plus PEG2b/RBV. At treatment Week 36 participants will be assigned to the following treatments depending on the virologic response at Week 8 and cirrhotic status:
- For non-cirrhotic participants with undetectable hepatitis C virus (HCV)-RNA on Week 8, all treatment will be discontinued at Week 36.
- For non-cirrhotic participants with detectable HCV-RNA on Week 8, only boceprevir treatment will be discontinued at Week 36 and PEG2b and RBV treatment will continue to Week 48.
- For cirrhotic participants, the boceprevir plus PEG2b/RBV treatment will continue to Week 48.
The study has a futility rule at Week 12 at which point all subjects with detectable HCV-RNA levels will be discontinued. All participants will have a post-treatment follow-up period of at least 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Weight ≥ 40 kg to ≤ 125 kg
- •Sexually active male participants and female participants of child-bearing potential must agree to use a medically acceptable form of contraception
- •Must have documented Chronic Hepatitis C Genotype 1 infection
- •Must have failed prior treatment with interferon plus ribavirin
- •Must have completed treatment with interferon plus ribavirin for at least 12 weeks
- •Must have had a liver biopsy or Fibroscan to determine status as cirrhotic or non-cirrhotic
- •Participants with cirrhosis must have had an ultrasound or imaging study within 6 months of the Screening visit
排除标准
- •Known co-infection with the human immunodeficiency virus (HIV) or the hepatitis B virus
- •Prior discontinuation of treatment with interferon or ribavirin due to the occurrence of an adverse event(s) considered by the investigator to be possibly or probably related to the treatment
- •Treatment with ribavirin within 90 days and any interferon within 1 month of the Screening visit
- •Treatment with any investigational drug within 30 days prior to the Screening visit
- •Treatment with midazolam, pimozide, amiodarone, flecainide, propafenone, quinidine, or ergot derivatives within 2 weeks prior to the Day 1 visit
- •Participation in any investigational trial within 30 days of the Screening visit
- •Evidence of decompensated liver disease
- •Child Pugh score > 6 (Class B and C)
- •Diabetic and/or hypertensive participants with clinically significant ocular examination findings
- •Pre-existing psychiatric conditions
- •Clinical diagnosis of substance abuse
- •Active or suspected malignancy
- •Pregnant or nursing
研究组 & 干预措施
Peg2b + Ribavirin + Boceprevir
Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
干预措施: Peginterferon Alfa-2b 1.5 mcg/kg/week (Drug)
Peg2b + Ribavirin + Boceprevir
Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
干预措施: Boceprevir (Drug)
Peg2b + Ribavirin + Boceprevir
Peginterferon alpha-2b (Peg2b) plus ribavirin (RBV) starting on Day 1 and boceprevir starting on Week 5
干预措施: Ribavirin (Drug)
结局指标
主要结局
Percentage of Participants Achieving Sustained Virologic Response (SVR)
时间窗: Follow-Up Week 24
Percentage of Participants Experiencing a Serious Adverse Event (SAE) During the Study Therapy Period
时间窗: Treatment Week 1 to Treatment Week 24
次要结局
未报告次要终点